La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Australian Clinical Labs Croissance future

Future contrôle des critères 4/6

Australian Clinical Labs is forecast to grow earnings and revenue by 21% and 4.6% per annum respectively. EPS is expected to grow by 20.8% per annum. Return on equity is forecast to be 21.6% in 3 years.

Informations clés

21.0%

Taux de croissance des bénéfices

20.8%

Taux de croissance du BPA

Healthcare croissance des bénéfices	17.0%
Taux de croissance des recettes	4.6%
Rendement futur des capitaux propres	21.6%
Couverture par les analystes	Good
Dernière mise à jour	06 Aug 2024

Mises à jour récentes de la croissance future

Recent updates

Here's Why We Think Australian Clinical Labs (ASX:ACL) Might Deserve Your Attention Today

Aug 14

Australian Clinical Labs Limited (ASX:ACL) Just Reported Half-Year Earnings: Have Analysts Changed Their Mind On The Stock?

Feb 25

New Forecasts: Here's What Analysts Think The Future Holds For Australian Clinical Labs Limited (ASX:ACL)

Dec 22

The Market Lifts Australian Clinical Labs Limited (ASX:ACL) Shares 31% But It Can Do More

Dec 21

The Strong Earnings Posted By Australian Clinical Labs (ASX:ACL) Are A Good Indication Of The Strength Of The Business

Sep 01

Prévisions de croissance des bénéfices et des revenus

ASX:ACL - Estimations futures des analystes et données financières antérieures (AUD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
6/30/2027	794	49	50	61	2
6/30/2026	749	44	76	174	8
6/30/2025	713	38	71	166	9
6/30/2024	685	28	60	151	9
12/31/2023	674	15	147	154	N/A
9/30/2023	686	26	142	149	N/A
6/30/2023	697	36	137	144	N/A
3/31/2023	757	55	143	154	N/A
12/31/2022	818	73	148	165	N/A
9/30/2022	907	126	206	225	N/A
6/30/2022	996	178	263	284	N/A
3/31/2022	931	156	238	256	N/A
12/31/2021	867	134	214	228	N/A
9/30/2021	757	97	179	191	N/A
6/30/2021	647	60	144	154	N/A
3/31/2021	598	79	N/A	N/A	N/A
12/31/2020	549	98	N/A	N/A	N/A
9/30/2020	520	70	N/A	N/A	N/A
6/30/2020	491	41	92	102	N/A
6/30/2019	448	-11	-13	1	N/A
6/30/2018	379	-9	-4	5	N/A
6/30/2017	340	-24	N/A	5	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: ACL's forecast earnings growth (21% per year) is above the savings rate (2.4%).

Bénéfices vs marché: ACL's earnings (21% per year) are forecast to grow faster than the Australian market (13.1% per year).

Croissance élevée des bénéfices: ACL's earnings are expected to grow significantly over the next 3 years.

Chiffre d'affaires vs marché: ACL's revenue (4.6% per year) is forecast to grow slower than the Australian market (5.4% per year).

Croissance élevée des revenus: ACL's revenue (4.6% per year) is forecast to grow slower than 20% per year.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: ACL's Return on Equity is forecast to be high in 3 years time (21.6%)

Australian Clinical Labs Croissance future

Future contrôle des critères 4/6

Informations clés

Mises à jour récentes de la croissance future

Consensus EPS estimates fall by 20%

Price target decreased by 7.5% to AU$3.56

Consensus EPS estimates fall by 21%

Price target increased by 7.1% to AU$4.03

Price target decreased by 8.5% to AU$3.76

Price target decreased to AU$4.27

Recent updates

Australian Clinical Labs Limited to Report Fiscal Year 2024 Results on Aug 29, 2024

Australian Clinical Labs Limited, Annual General Meeting, Oct 25, 2024

We Think Australian Clinical Labs (ASX:ACL) Is Taking Some Risk With Its Debt

Upcoming dividend of AU$0.03 per share

Consensus EPS estimates fall by 20%

First half dividend reduced to AU$0.03

First half 2024 earnings released: EPS: AU$0.025 (vs AU$0.13 in 1H 2023)

Are Investors Undervaluing Australian Clinical Labs Limited (ASX:ACL) By 46%?

Australian Clinical Labs Limited to Report First Half, 2024 Results on Feb 28, 2024

Is It Time To Consider Buying Australian Clinical Labs Limited (ASX:ACL)?

Price target decreased by 7.5% to AU$3.56

Upcoming dividend of AU$0.07 per share at 4.6% yield

Consensus EPS estimates fall by 21%

Australian Clinical Labs Limited Announces Appointment of Christine Bartlett as Non-Executive Director

Australian Clinical Labs Limited Declares Full Year Fully Franked Dividend for the Fiscal Year 2023, Payable on 3 October 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of AU$0.07 per share at 13% yield

Price target increased by 7.1% to AU$4.03

First half 2023 earnings released: EPS: AU$0.13 (vs AU$0.65 in 1H 2022)

Australian Clinical Labs Limited Announces Dividend for the Six Months Ended December 31, 2022, Payable on April 26, 2023

Investor sentiment improves as stock rises 16%

Price target decreased by 8.5% to AU$3.76

Price target decreased to AU$4.27

High number of new and inexperienced directors

Price target decreased to AU$4.62

Independent Non-Executive Director recently sold AU$71k worth of stock

Australian Clinical Labs Limited Announces Resignation of Dr. Michael Stanford as Non-Executive Director

Australian Clinical Labs Limited, Annual General Meeting, Oct 25, 2023

Independent Non-Executive Director recently sold AU$140k worth of stock

Upcoming dividend of AU$0.41 per share

Here's Why We Think Australian Clinical Labs (ASX:ACL) Might Deserve Your Attention Today

Full year 2022 earnings: EPS misses analyst expectations

Price target decreased to AU$5.30

Australian Clinical Labs Limited Declares Dividend for the Period of Six Months Ended 30 June 2022

Investor sentiment deteriorated over the past week

CEO & Executive Director recently bought AU$335k worth of stock

High number of new and inexperienced directors

First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Australian Clinical Labs Limited Declares Ordinary Dividend for the Period of Six Months December 31, 2021, Payable April 21, 2022

Australian Clinical Labs Limited (ASX:ACL) Just Reported Half-Year Earnings: Have Analysts Changed Their Mind On The Stock?

Australian Clinical Labs Limited Revises Earnings Guidance for the First Half 2022

New Forecasts: Here's What Analysts Think The Future Holds For Australian Clinical Labs Limited (ASX:ACL)

The Market Lifts Australian Clinical Labs Limited (ASX:ACL) Shares 31% But It Can Do More

Investor sentiment improved over the past week

Consensus EPS estimates increase by 46%

Australian Clinical Labs Limited (ASX:ACL) completed the acquisition of Medlab Pathology Pty Ltd.

Independent Non-Executive Director recently bought AU$99k worth of stock

The Strong Earnings Posted By Australian Clinical Labs (ASX:ACL) Are A Good Indication Of The Strength Of The Business

Full year 2021 earnings released: EPS AU$0.40 (vs AU$0.28 in FY 2020)

Australian Clinical Labs Limited Provides Earnings Guidance for the Fiscal Year of 2021

Australian Clinical Labs Limited has completed an IPO in the amount of AUD 408.559209 million.

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance